ICER Will Explore Link Between Reasonable Drug Pricing And ‘Fair’ US Formulary Policies
Executive Summary
Study will examine prior authorization and other access restrictions at 15 of the largest US commercial payers for a group of 27 drugs.
You may also be interested in...
Cigna Switch Program Intensifies Competitive Dynamics For Cosentyx
A new pilot program by the insurer is offering a $500 debit card to patients who switch from the blockbuster Novartis psoriasis drug to Lilly's rival Taltz or other preferred drugs.
Medicare Part B Premium Reduction In 2023 Has Reserves Built In If Lecanemab Launches
But premiums in future years made need to keep pace with accelerating Medicare spending on Alzheimer’s drugs.
Lecanemab And Medicare: Could Better FDA/CMS Communication Improve Coverage Chances?
Eisai/Biogen’s promising Phase III data fueling the companies’ hopes that Medicare will relax coverage restrictions for their Alzheimer’s treatment candidate. If the sponsors fail to change the NCD, lecanemab will need to rely on a registry for reimbursement after full approval.